No 03 2024

The Gates Foundation, Novo Nordisk Foundation, and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a USD 50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Abera Bioscience reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results in the mouse model.

All participants are determined to establish Europe as a global leader in Artificial Intelligence (AI), advancing AI development and application.

Pharming Technologies declares unconditional and completes the recommended cash offer to the shareholders of Abliva and extends the acceptance period.

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation in a carve-out transaction from Mitsubishi Chemical Group Corporation.

Boule Diagnostics has entered into an exclusive distribution agreement with VitalScientific for the US market.